Harpoon Therapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $31.9M | $23.7M | $3.3M | $1.1M | $4.8M | $708,000 |
| Operating income | −$68.3M | −$116.8M | −$13.1M | −$14.2M | −$27.7M | −$16.5M |
| Net income | −$67.7M | −$116.7M | −$12.6M | −$13.6M | −$27.4M | −$16.8M |
| Total assets | $73.7M | $155.5M | $171.6M | $176.6M | $102.6M | $31.9M |
| Total liabilities | $68.3M | $97.4M | $117.8M | $82.4M | $26.5M | $19.0M |
| Equity | $5.4M | $58.1M | $53.8M | $94.2M | −$53.5M | −$26.9M |
| EPS (diluted) | $-2.04 | $-3.62 | $-1.99 | — | — | — |
| Shares out. | 33.0M | 32.4M | 24.9M | 24.3M | 1.4M | 1.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −214.1%
- Net margin
- −212.2%
- Return on equity
- −1254.5%
- Return on assets
- −91.9%
- Return on capital (ROCE)
- −320.8%
- Liabilities / assets
- 92.7%
- Debt / equity
- 12.66×
- Book value / share
- $0.16
- Revenue growth (YoY)
- 34.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -21.53distress
- Accruals / assets
- 29.1%high accruals
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-12-31Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
- Phase 1/2Active Not Recruitingreadout ~2028-01-28A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 11, 2024
- Shareholder voteMar 8, 2024
- Other material eventFeb 28, 2024
- Other material eventFeb 22, 2024
- Amended charter or bylawsJan 29, 2024
- Other material eventJan 26, 2024
- Entered a material agreement · Director / officer change · Regulation FD disclosureJan 8, 2024
- Director / officer changeNov 28, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.